From Clinical Trial Efficacy to Real-World Effectiveness First Ajovy® ▼ (fremanezumab) Data from European Real World Evidence Program

8 November 2021, Teva Germany (GmbH) presented at the DGN Congress 2021 the first interim analysis results of the FINESSE study aiming to provide real-world evidence of fremanezumab treatment outcomes by evaluating effectiveness in routine clinical practice.

Read the source article at CentralCharts
2021-11-08 10:25:00